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High intravenous doses of vitamin C (ascorbic acid) have been reported to benefit cancer
patients, but the data are controversial and there is incomplete knowledge of what physio-
logical mechanisms might be involved in any response. Vitamin C is taken up efficiently by
cells expressing SVCT2 transporters and since vascular endothelial cells express SVCT2, we
explored the hypothesis that administration of high-dose vitamin C (up to 5 g/kg) to mice
might affect vascular endothelial function. A single administration of vitamin C to mice
induced time- and dose-dependent increases in plasma concentrations of the serotonin
metabolite 5-hydroxyindole acetic acid (5-HIAA), a marker for vascular disrupting effects.
Responses were comparable to those for the tumor vascular disrupting agents, vadimezan
and fosbretabulin. High-dose vitamin C administration decreased tumor serotonin concen-
trations, consistent with the release of serotonin from platelets and its metabolism to
5-HIAA. High-dose vitamin C also significantly increased the degree of hemorrhagic necro-
sis in tumors removed after 24 h, and significantly decreased tumor volume after 2 days.
However, the effect on tumor growth was temporary.The results support the concept that
vitamin C at high dose increases endothelial permeability, allowing platelets to escape
and release serotonin. Plasma 5-HIAA concentrations could provide a pharmacodynamic
biomarker for vitamin C effects in clinical studies.
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INTRODUCTION
The physiological effects of orally administered vitamin C as an
antioxidant and in preventing scurvy are well known (1–3). Vit-
amin C at physiological concentrations generally has a protective
effect on the vascular endothelium, decreasing its permeability (3).
Plasma concentrations of vitamin C in humans following high oral
doses are limited by absorption, but intravenous administration
can overcome this limitation and lead to millimolar plasma con-
centrations (4, 5).Vitamin C at high dose can inhibit tumor growth
in mice (6–9) and early studies reported that administration of
vitamin C at high intravenous doses to cancer patients increased
survival by more than 5 months (10, 11). However, subsequent
clinical studies were conflicting and there is currently no clear res-
olution of the question of whether high-dose intravenous vitamin
C affects patient survival (12). Progress in our understanding of
the action of high-dose vitamin C has been hampered by a lack of
appropriate biomarkers for physiological responses to vitamin C.
There is good evidence that tumors have a disorganized and
inefficient blood supply as compared to normal tissues. This leads
to metabolic and hypoxic stress, to the induction of hypoxia-
inducible factor-1α (HIF-1α) (13), and to increased production
of vascular endothelial growth factor (VEGF), also called vascu-
lar permeability factor (14). The resulting increase in vascular
permeability leads to reduced tumor blood flow (15). Vascular
disrupting agents are thought to act by further increasing vascu-
lar permeability, thus reducing tumor blood flow to the point of
vascular failure (16, 17). Several vascular disrupting agents have
advanced to clinical trial, most notably vadimezan (DMXAA) in
non-small cell lung cancer (18) and fosbretabulin (combretastatin
A4-phosphate; CA4-P) in thyroid cancer (19). In this preliminary
study, we have investigated the hypothesis that vitamin C adminis-
tered at high dose can act as vascular disrupting agent. The basis for
this hypothesis is that vascular endothelial cells, through expres-
sion of the SVCT2 transporter (2, 20, 21), concentrate cytoplasmic
vitamin C to a point where it affects vascular function.
Measurement of the clinical effects of vascular disrupting
agents has generally been carried out with the use of contrast-
enhanced magnetic resonance (22, 23). A paramagnetic contrast
agent such as gadolinium–diethylenetriamine pentaacetic acid,
which binds tightly to albumin, is administered. Increased vascu-
lar permeability in tumor tissue leads to extravasation and tissue
retention of this protein-bound agent, concentrations of which can
be measured using magnetic resonance. In experimental studies, a
similar strategy is employed using the dye Evans Blue, which like
the gadolinium derivative is tightly bound to albumin in plasma.
Increased vascular permeability in tumor tissue leads to extrava-
sation of the albumin–dye complex, which can be measured by a
photometric assay (24). In previous studies, we have proposed that
extravasation of platelets could also be used to detect increased
vascular permeability (16). Serotonin (5-hydroxytryptamine; 5-
HT) is localized in platelets as a consequence of the action of
vesicular monoamine transporters, which also concentrate sero-
tonin into chromaffin granules of the adrenal medulla and into
neurons (25). Tumor tissue concentrations of serotonin therefore
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largely reflect platelet content of serotonin. Increased vascular
permeability leads to extravasation of platelets, to platelet acti-
vation (for instance, by extravascular contact with collagen) and
to serotonin release (26). Free serotonin is converted by hepatic
metabolism to 5-hydroxyindole acetic acid (5-HIAA), which can
be measured by high-performance liquid chromatography (27,
28). Thus, increased vascular permeability leads to serotonin loss
from platelet and to increased free concentrations of serotonin and
5-HIAA.
Previous preclinical studies have shown increased plasma con-
centrations of 5-HIAA and serotonin in response to a number
of vascular disrupting agents including flavone acetic acid (FAA),
vadimezan, vinblastine, and colchicine (27, 30, 31). In the case of
vadimezan, increases in plasma 5-HIAA concentrations are highly
correlated with increased extravasation of Evans Blue into tumor
tissue as a marker of tumor vascular permeability (r = 0.82), as
well as with decreased tumor blood flow (r = 0.73) (24, 32). A
Phase 1 clinical trial of vadimezan has shown that plasma 5-HIAA
concentrations increase in response to the drug (28, 29), and a
Phase 2 trial has shown that increases in 5-HIAA correlate posi-
tively with dose (33). Here, we have measured increases in plasma
5-HIAA concentrations in mice treated with high doses of vitamin
C, comparing them with those of vadimezan. We also include data
showing the 5-HIAA response to the vascular disrupting agent
fosbretabulin. We have examined the effect of high-dose vitamin
C on tissue serotonin concentrations in tumor and liver, and on
the growth of Colon 38 tumors in mice.
MATERIALS AND METHODS
MATERIALS
Vadimezan was synthesized in this laboratory (34), dissolved in
sterile saline, protected from light, and injected into the peritoneal
cavity in a volume of 10µl/g body weight. Vitamin C was used
as a solution in clinical vial (McGuff Pharmaceuticals Ltd., New
Zealand) and diluted with water to the appropriate concentration
before injection in a volume of 10µl/g body weight. Fosbretab-
ulin, kindly provided by Cancer Research UK, was dissolved in
dimethylsulfoxide (10 mg/ml) and injected in a volume of 2.5µl/g
body weight. Other biochemicals were from Sigma.
MICE AND TUMORS
All experiments were approved by the Animal Ethics Commit-
tee of the University of Auckland. C57Bl/6 mice were bred and
housed under controlled temperature, humidity, and lighting.
Mice between 6 and 12 weeks of age (18–22 g) were used. Samples
of murine Colon 38 carcinomas (1 mm3 tumor fragments from a
carrier mouse) were implanted subcutaneously in mice that had
been anesthetized by intraperitoneal administration (10 l/g body
weight) of a xylazine (10 mg/kg)/ketamine (150 mg/kg) mixture.
Treatment was commenced 12–14 days after implantation, when
tumors were approximately 5 mm in diameter. Tumor growth
delay experiments utilized groups of five mice; tumor size was mea-
sured with calipers and volumes were calculated as (a2b), where
a and b are the minor and major tumor axes, respectively. Tumor
histology was carried out on a group of mice with larger tumors
(5–8 mm in diameter). Mice were treated with vitamin C (4 g/kg)
and tumors were removed after 24 h, fixed with formalin, and
sections stained with hematoxylin/eosin (35). The whole tumor
section (largest diameter) was photographed and a grid was super-
imposed on the photograph. Each section of the grid was then
analyzed for hemorrhagic tumor necrosis (i.e., lack of stained
nuclei) and the combined results used to derive an estimate of
the proportion of necrosis.
MEASUREMENT OF SEROTONIN AND 5-HIAA IN PLASMA AND TUMOR
SAMPLES
General methods for the measurement of plasma, tumor, and
liver tissue concentrations of serotonin and 5-HIAA have been
described previously (27, 36). For both the time course and
dose dependence studies, blood was collected from groups of
three terminally anesthetized mice through the ocular sinus
into heparinized polypropylene microcentrifuge tubes containing
20µl of 7.5% sodium ethylenediamine tetra-acetate (EDTA) and
1 mg sodium ascorbate. Tumor and liver tissue were homogenized
in 7.5% EDTA/0.02% sodium ascorbate (1 ml for tumor tissue
and 2 ml for in liver tissue). Tubes were centrifuged (5,000× g ;
10 min), and plasma samples were removed and deproteinized
by addition of 1 ml of ice-cold acetonitrile:water (3:1) to 100µl
plasma. After mixing and centrifugation (3,000× g ; 15 min; 4°C),
the supernatants were concentrated in a centrifugal vacuum
concentrator, reconstituted in 100µl mobile phase [80% ace-
tonitrile:45 mM formate buffer (35:63)]. Liver and tumor tissue
homogenates were resuspended in mobile phase.
5-HIAA was analyzed by high-performance liquid chromatog-
raphy using a LUNA C18 5µm 75 mm× 4.6 mm stainless steel
column (Phenomenex, Torrence, CA, USA) with a Phenomenex
C18 Security guard column. The mobile phase was 0.14 M potas-
sium phosphate buffer pH 4.50 containing 15% methanol, 5% ace-
tonitrile, and 0.004% acetyltrimethyl-ammonium bromide, 2 mM
NaCl, and 0.1 mM EDTA. 5-HIAA was detected using a Model
DECADE II Electrochemical Detector (Antec Leyden, Nether-
lands) with an electrode potential of 400 mV. Quantitation was
carried out by reference to a standard curve. Serotonin was ana-
lyzed using a LUNA C8 5µm 150 mm× 3.0 mm stainless steel with
a Phenomenex C18 Security guard column. The mobile phase was
85% 0.14 M potassium phosphate buffer pH 4.50/15% acetonitrile
together with 1 g/l 1-octansulfonic acid sodium salt. Serotonin was
detected using a Shimadzu RF-10AXL fluorescence detector and
quantitation utilized N -acetyl serotonin as an internal standard.
STATISTICAL ANALYSIS
Values are quoted as means± standard errors. Groups were com-
pared using routines available on SigmaPlot. Student’s t -test was
used when the data were normally distributed and a Rank Sum
test was used when the data were not normally distributed.
RESULTS
EFFECTS OF VITAMIN C TREATMENT ON SEROTONIN AND 5-HIAA
CONCENTRATIONS
Mice were found to tolerate a single intraperitoneal dose of vita-
min C (5 g/kg), which was comparable to that (4 g/kg) used in a
previously published study (6). No obvious toxicity was observed
although following drug administration, cooling of mouse skin
and reduced motor activity was observed for several hours.
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Plasma concentrations of 5-HIAA rose significantly (p< 0.05 at
2 h;< 0.001 at 2 and 4 h) with increasing time in groups of three
non-tumor-bearing mice treated with a single dose of vitamin C
(5 g/kg), as shown in Figure 1A. The dose response of plasma
5-HIAA in groups of six non-tumor-bearing mice was also mea-
sured 2 h after a single dose of Vitamin C (Figure 1B); plasma
concentrations increased significantly (p< 0.05) following doses
of 2 and 4 g/kg. The plasma 5-HIAA response to vitamin C was
compared to those of two established vascular disrupting agents.
New data for groups of three non-tumor-bearing mice treated with
fosbretabulin (25 mg/kg) are shown in Figure 2 and indicate that
plasma 5-HIAA concentrations increase significantly (p< 0.05) at
both time points. The results for fosbretabulin have been com-
pared with previously published data (36) for non-tumor-bearing
mice treated with vadimezan (25 mg/kg).
5-HIAA is a hepatic metabolite of serotonin, which is stored
in platelets within tissues. Serotonin concentrations were there-
fore measured in plasma, tumor tissue, and liver tissue of groups
of 3 Colon 38 tumor-bearing mice either 4 or 24 h after admin-
istration of a single dose of vitamin C (4 g/kg). Serotonin con-
centrations increased in plasma after 4 h, but the difference was
not significant (Figure 3A). Serotonin concentrations in tumor
tissue decreased significantly (p< 0.05) after 24 h (Figure 3B)
but increased significantly (p< 0.05) in liver tissue after 4 h
(Figure 3C).
EFFECTS OF VITAMIN C TREATMENT ON COLON 38 TUMOR GROWTH
IN VIVO
Mice with subcutaneous Colon 38 murine adenocarcinomas were
treated with a single dose of vitamin C (4 g/kg), and tumors
were removed after 24 h for histology. Tumors from five vitamin
C-treated mice were red in color while those from seven con-
trol mice were white. Stained tumor sections (Figure 4) from
vitamin C-treated mice showed larger areas of necrotic cells
(62± 4%) than did control mice (22± 5%) and the difference was
FIGURE 1 | Plasma concentrations of 5-HIAA following a single i.p.
administration of vitamin C are shown. (A) Time course for
non-tumor-bearing mice following administration of vitamin C (5 g/kg; filled
circles) or with no treatment (open circles). (B) Dose curve for
non-tumor-bearing mice following administration of vitamin C (0–4 g/kg).
Vertical bars in each case represent SEM.
significant (p< 0.01). Mice with subcutaneous Colon 38 murine
adenocarcinomas (five per group; approximately 5 mm in diam-
eter; 62± 16 mm3) were treated with a single dose of vitamin
C (4 g/kg), and tumor volumes were measured at various times
later. After 2 days, the tumor volumes (relative to the starting vol-
ume) were 1.92± 0.51 for the control group and 0.50± 0.19 for
the treated group, a significant reduction (p= 0.03) than those
of the control group, but thereafter tumor growth in the treated
group was slightly higher than that in the control group and by
10 days, treated and control tumors had similar average volumes
(Figure 5).
DISCUSSION
The results provide preliminary evidence for the hypothesis that
high-dose vitamin C has a tumor vascular disrupting effect in mice.
Tumors removed from mice 24 h after treatment with vitamin C
were red in color while tumors from control mice were white;
this was similar to what was found previously with vadimezan
and other vascular disrupting agents (results not shown). Tumor
sections from vitamin C-treated mice (Figure 4) showed signifi-
cantly larger areas of necrotic tumor tissue than did those from
control tumors (62 versus 22%, respectively), although the effect
was not as great as that induced by vadimezan and several other
vascular disrupting drugs. Tumor-bearing mice treated with vita-
min C (4 g/kg) responded with an initial decrease in tumor volume
after 2 days followed by a phase of more rapid tumor growth
(Figure 5), again similar to that caused by a suboptimal dose of
vadimezan. It is clear, at least with the Colon 38 tumor, that vit-
amin C administered at a single high dose is less effective than
vadimezan, but it should be kept in mind that vadimezan may dif-
fer from vitamin C by having two actions, a direct one on tumor
endothelial cells (37) and an indirect one mediated by cytokine
induction (16, 38). Further experiments with multiple doses and
FIGURE 2 | Comparison of plasma concentrations of 5-HIAA in
non-tumor-bearing mice following i.p. administration of
(A) fosbretabulin (25 mg/kg) and (B) vadimezan (25 mg/kg). Data for
vadimezan are extracted from a previous publication (36). Vertical bars
represent SEM (three mice per group).
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FIGURE 3 | Concentrations of serotonin in plasma (A), Colon 38 subcutaneous tumor tissue (B), and liver tissue (C), measured before or at the
indicated time after i.p. administration of vitamin C (4 g/kg). Vertical bars represent SEM (three mice per group).
FIGURE 4 | Histological appearance of representative sections of mice
with subcutaneous Colon 38 tumors is shown. Bars indicate 20µm.
(A) No treatment: intact cells can be seen by purple nuclei with occasional
pink spaces indicating necrosis. (B) Twenty-four hours after i.p.
administration of vitamin C (4 g/kg): the large rather featureless pink regions
indicate areas of hemorrhagic necrosis.
other tumor types would be required to fully characterize this
vascular disrupting effect of vitamin C.
Vascular disrupting agents affect the normal vascular endothe-
lium as well as the tumor vascular endothelium (24). The increased
plasma 5-HIAA concentrations in non-tumor-bearing mice in
response to vitamin C (Figure 1) are consistent with an effect
on normal vasculature. Cooling of mouse skin, observed for sev-
eral hours after administration of the maximum tolerated dose
of vitamin C (5 g/kg), resemble that observed in mice treated with
vadimezan and also suggest an effect on normal endothelium. Skin
cooling has been interpreted as arising from inhibition of capillary
blood flow in normal skin (32). It was of interest that serotonin
concentrations in liver were, in contrast to those in tumor tissue,
elevated after 4 h (Figure 3C). The observation again suggests an
effect on normal tissues and several explanations are possible, such
as increased trafficking of platelets to the liver.
Vascular disrupting agents can be divided into two classes, the
first comprising tubulin binders and the second comprising FAA,
FIGURE 5 | Growth of subcutaneous Colon 38 tumors following i.p.
administration of vitamin C (4 g/kg) (filled circles) as compared to
control mice (open circles) is shown. Vertical bars represent SEM (five
mice per group).
xanthenone acetic acid (XAA), and a variety of XAA analogs
including vadimezan (16, 39). The present study suggests that
vitamin C is a member of the second class, raising the question
of whether acidic character is important for the activity of this
class. It is clear at least from studies of FAA and XAA analogs in
mice, that activity has quite exacting structural requirements (40).
Cells normally exclude acidic molecules and uptake is likely to
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depend on the expression of appropriate drug transporters (41).
In the case of vitamin C, uptake is thought to be strongly depen-
dent on the expression of cellular vitamin C transporters; the
SVCT2 transporter is highly expressed in both endothelial cells
and macrophages and results in millimolar intracellular concen-
trations (2, 42). It would be interesting to determine whether the
vascular disrupting activity of other members of this second class
is dependent on the expression of transporters that are expressed
in endothelial cells.
The molecular targets of vitamin C in endothelial cells are still
being characterized. One possible target is tetrahydrobiopterin,
whose stabilization by vitamin C leads to nitric oxide production,
S-nitrosation of multiple proteins (43, 44), and increased endothe-
lial permeability (45). Tetrahydrobiopterin is also an essential
cofactor for tryptophan hydroxylase (46), and stabilization might
also lead to increased serotonin production, potentially explaining
the increased liver serotonin concentrations (Figure 3C). Another
possible target of vitamin C is HIF-1 hydroxylase; by stabilizing
this enzyme, vitamin C may inhibit induction of the transcription
factor (HIF-1) and thus inhibit the induction of multiple genes by
HIF-1 (47).
It is not yet possible to determine whether the effects observed
here in mice are relevant to any effects of high-dose intravenous
vitamin C in humans. Plasma concentrations of vitamin C were
not measured in this study but published data with mice show
that they are likely to reach 40 mM following a dose of 4 g/kg (6).
Studies in humans administered high-dose intravenous vitamin
C have reported comparable plasma concentrations of 24 mM
(5). It seems likely that vascular disruptive properties of high-
dose vitamin C, if they occur in human tumors, would not be the
sole contributor to any possible antitumor effect; other cells that
express SVCT2 transporters, such as cells of the innate immune
system, might also be affected. In any future clinical trials designed
to test the clinical effects of high-dose vitamin C administration,
plasma 5-HIAA might prove to be a useful biomarker.
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